Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age

BACKGROUND: Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1), administered to 12–23-month-old RSV-seropo...

Descripción completa

Detalles Bibliográficos
Autores principales: Díez-Domingo, Javier, Sáez-Llorens, Xavier, Rodriguez-Weber, Miguel A, Epalza, Cristina, Chatterjee, Archana, Chiu, Cheng-Hsun, Lin, Chien-Yu, Berry, Andrea A, Martinón-Torres, Federico, Baquero-Artigao, Fernando, Langley, Joanne M, Ramos Amador, José T, Domachowske, Joseph B, Huang, Li-Min, Chiu, Nan-Chang, Esposito, Susanna, Moris, Philippe, Lien-Anh Nguyen, Thi, Nikic, Vanja, Woo, Wayne, Zhou, Yingjun, Dieussaert, Ilse, Leach, Amanda, Gonzalez Lopez, Antonio, Vanhoutte, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226655/
https://www.ncbi.nlm.nih.gov/pubmed/36484484
http://dx.doi.org/10.1093/infdis/jiac481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226655/
https://www.ncbi.nlm.nih.gov/pubmed/36484484
http://dx.doi.org/10.1093/infdis/jiac481

Ejemplares similares